• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register

CCG1423

Product ID C0824
Cas No. 285986-88-1
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $61.50 In stock
5 mg $99.60 In stock
25 mg $344.40 In stock
Bulk Quote
Add to Wishlist

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

CCG1423 is an inhibitor of Rho signaling that inhibits serum response factor (SRF); it displays anti-metastatic, anti-diabetic, and anti-fibrotic activities. CCG1423 binds myocardin-related transcription factor A (MRTF-A), preventing its accumulation and potentially inhibiting the epithelial-to-mesenchymal transition (EMT). CCG1423 also inhibits invasiveness of prostate cancer cells. In animal models of diabetes pathogenesis, this compound improves glucose uptake and tolerance.

Product Info

Cas No.

285986-88-1

Purity

≥98%

Formula

C18H13ClF6N2O3

Formula Wt.

454.75

Chemical Name

n-(2-(4-Chloroanilino)-1-methyl-2-oxoethoxy)-3,5-bis(trifluoromethyl)benzamide

IUPAC Name

N-({1-[(4-Chlorophenyl)amino]-1-oxo-2-propanyl}oxy)-3,5-bis(trifluoromethyl)benzamide

Solubility

DMSO: 90 mg/mL

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

C0824 MSDS PDF

Info Sheet

C0824 Info Sheet PDF

References

Hayashi K, Watanabe B, Nakagawa Y, et al. RPEL proteins are the molecular targets for CCG-1423, an inhibitor of Rho signaling. PLoS One. 2014 Feb 18;9(2):e89016. PMID: 24558465.

Bell JL, Haak AJ, Wade SM, et al. Optimization of novel nipecotic bis(amide) inhibitors of the Rho/MKL1/SRF transcriptional pathway as potential anti-metastasis agents. Bioorg Med Chem Lett. 2013 Jul 1;23(13):3826-32. PMID: 23707258.

Jin W, Goldfine AB, Boes T, et al. Increased SRF transcriptional activity in human and mouse skeletal muscle is a signature of insulin resistance. J Clin Invest. 2011 Mar;121(3):918-29. PMID: 21393865.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2023 LKT Laboratories, All Rights Reserved - Products for research use only